Compare KraneShares Hang Seng TECH Index ETF (KTEC) vs Maravai LifeSciences Holdings Inc. Class A Common Stock (MRVI) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
KraneShares Hang Seng TECH Index ETF vs Maravai LifeSciences Holdings Inc. Class A Common Stock — how do they compare? KraneShares Hang Seng TECH Index ETF trades at $11.52 (market cap $46.22M), while Maravai LifeSciences Holdings Inc. Class A Common Stock trades at $6.56 (market cap $972.90M). The key difference: Maravai LifeSciences Holdings Inc. Class A Common Stock is far larger — about 21× KraneShares Hang Seng TECH Index ETF's market cap, and Maravai LifeSciences Holdings Inc. Class A Common Stock is trading nearer its 52-week high, KraneShares Hang Seng TECH Index ETF nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold KraneShares Hang Seng TECH Index ETF for 44 Days and Maravai LifeSciences Holdings Inc. Class A Common Stock for 0 Days on average.
| KTEC | MRVI | |
|---|---|---|
Market Cap | $46.22M | $972.90M |
Volume | 22,698 | 4,325,710 |
Sector | Sector/Thematic | Health |
52-Week High | $18.36 | $9.00 |
52-Week Low | $11.41 | $2.83 |
Typical Hold Time | 44 Days | 0 Days |
Enterprise Value | — | $1.08B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
KTEC trades at $11.61 with no recent price movement. The stock shows bearish technical signals with 15 sell indicators versus 2 buy signals. Fundamentally, the company reported $120.04M revenue in 2016 with a net loss of $697K, though cash flow improved to positive $2.77M. Recent news highlights China's AI competition potentially benefiting tech ETFs like KTEC.
KTEC faces mixed prospects with improving cash flow but inconsistent profitability. The bearish technical outlook and volatile earnings history suggest caution, though exposure to AI sector growth through ETF positioning offers potential upside. Key risks include competitive pressures and execution challenges in maintaining positive momentum.
Maravai LifeSciences (MRVI) trades at $6.53, down 7.51% in the last session amid mixed signals. The stock shows improving fundamentals with Q2 2026 revenue growth of 9% and three consecutive earnings beats, though it remains unprofitable with a -37.07% net margin. Technical analysis indicates neutral positioning with key support at $6 and resistance at $7. Recent news highlights patent expansions in China and institutional accumulation.
The outlook remains cautiously optimistic with analyst consensus pointing to 7% upside potential to the $7.00 price target. Key opportunities include margin expansion and RNA technology leadership, while risks center on persistent cash burn and competitive pressures in life sciences. The stock offers speculative growth potential for risk-tolerant investors.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About KraneShares Hang Seng TECH Index ETF
KTEC tracks the Hang Seng TECH Index, providing targeted exposure to the 30 largest technology companies listed on the Hong Kong Stock Exchange. It focuses on innovative, internet-based businesses across sectors like e-commerce, fintech, cloud computing, and digital technology.
Read more on KTEC →About Maravai LifeSciences Holdings Inc. Class A Common Stock
Maravai LifeSciences Holdings Inc. is a life sciences company supporting drug therapy, diagnostic, and vaccine development through four operating brands: TriLink BioTechnologies (nucleic acid and mRNA synthesis), Cygnus Technologies (biologics safety testing), Glen Research (oligonucleotide synthesis materials), and Alphazyme (enzyme manufacturing). It serves biotech and biopharma customers from discovery through commercial manufacturing.
Read more on MRVI →
